Plus Products Reports First Quarter 2020 Financial Results


SAN MATEO, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a cannabis branded products company in the U.S., today released its unaudited financial and operational results for the three months ended March 31, 2020, expressed in U.S. dollars. These filings are available for review on the Company’s SEDAR profile at www.sedar.com and on the Canadian Securities Exchange (the “CSE”) website at www.thecse.com.

Q1 2020 Financial Highlights

  • Revenues:  Net revenues climbed to $4.7M in Q1 2020, representing 46% year-over-year growth as compared to Q1 2019 net revenues of $3.2M and 36% quarter-over-quarter growth as compared to Q4 2019 net revenues of $3.5M. The Company continues to see revenue growth driven by its core operations in the California adult-use market, with contributions from the Nevada adult-use and national hemp CBD markets. In December 2019, the Company transitioned to a new California distributor, HERBL Distribution Solutions. This transition caused some sales, which otherwise would have taken place in December 2019, to be delayed until January 2020.
  • Gross Profits: Gross profits grew to $1.7M in Q1 2020 compared to $0.7M in Q1 2019. Gross profit margin in Q1 2020 was 35%, up from 21% in Q1 2019. Higher sales volumes and increasing operational efficiencies in the Company’s California production facility diminished the growth of labor and overhead costs relative to sales, thereby increasing gross profits.
  • Operating Profits (Losses): Operating losses were $(2.1)M in Q1 2020, representing a 31% improvement year-over-year from $(3.0)M in Q1 2019 and a 75% improvement quarter-over-quarter from $(8.2)M in Q4 2019. The Company implemented workforce reductions in Q1 2020 and required fewer upfront investments tied to new market entry than previous quarters, thus reducing its operating losses.
  • Cash Balance: The Company reported $14.2M in cash and cash equivalents at March 31, 2020. The Company made significant changes to its business in Q1 2020 to improve cash flow. As a result, cash and cash equivalents fell by $1.0M in Q1 2020, an 86% quarter-over-quarter improvement as compared to the Q4 2019 decrease of $7.1M. The Company experienced some one-time operational benefits to cash and cash equivalents in Q1 2020, but still anticipates a significantly lower rate of cash consumption in 2020 than in 2019.

Q1 2020 Business Highlights

  • In February 2020, the Company entered the wellness and relief segment of the California adult-use market with the introduction of its PLUS CBDRelief brand. The launch represents a significant extension beyond the core PLUS lineup. The new PLUS CBDRelief products were designed with low THC and high CBD ratios to serve the roughly one-third of consumers in the market that are looking to cannabis for relief.1 The new brand has already been picked up by over 175 licensed retailers across the state.
  • In March 2020, the Company announced a series of material changes to the business in an effort to prioritize an accelerated path towards becoming cash flow generative and continuing to establish itself as a leader in the California edibles market. These changes included workforce and salary reductions, as well as the conclusion of marketing agreements related to non-core businesses. In the first quarter, PLUS consumed $1.0M in cash and cash equivalents with $14.2M remaining on hand at March 31, 2020.

Management Commentary

“The start of this year came with a number of difficult decisions that were made in order to accelerate our path to cash flow generation,” stated Jake Heimark, Co-founder and CEO. “The changes we made helped to cut our cash consumption to less than a fifth of what it was last quarter and, critically, doing so did not undermine our core business which grew more than 35% quarter-over-quarter.

“Our first quarter financial results paint the picture of a much healthier business than previous quarters, but the work is far from done. In 2020, we are focused on leveraging our core capabilities to create capital-efficient growth through known distribution channels.

“To kick off this new strategic direction, we launched a second gummies brand, PLUS CBDRelief, mid-way through the first quarter. The new product line, which was developed with minimal capital investment and is designed to serve a subset of cannabis consumers not currently reached by the core PLUS brand, has already sold into over 175 licensed retailers.

“The rapid success of this initiative is a testament to both PLUS’s reputation for manufacturing innovative, high-quality products and the broad market reach we have built through years as a trusted leader in the California cannabis branded-products space.2

“The majority of our growth initiatives in 2020 will be centered around California. Despite experiencing some growing pains, we believe that California unequivocally remains the most valuable market for building a branded products company in cannabis. In 2019, the state made up 38% of the global adult-use market and is expected to remain 24% of that market through 2024.3

“With the two best-selling products in the state, and one of the largest brands in the California edibles market, we believe that we have established an exceptionally valuable position as a company.4 We are excited to take steps that we believe will continue to grow that position throughout the course of this year.

“In 2020, our strategic initiatives are built around three critical objectives: 1) ensuring the safety and health of our employees, customers, and partners during this pandemic; 2) establishing ourselves as the clear, long-term leader in California edibles; and 3) becoming a cash-flow positive business. We believe we are already executing on all three.”

Covid-19 Update     

In March 2020, there was a global outbreak of COVID-19, which continues to rapidly evolve. The extent to which the virus may impact the Company will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The ultimate geographic spread of the disease; the duration of the outbreak; travel restrictions; social distancing; business closures or business disruptions; and the effectiveness of actions taken in the United States and other countries to contain and treat the disease all remain unknown.

While cannabis has been deemed an essential business throughout most of California, it is still too early to understand how COVID-19 will impact PLUS or the market as a whole. To date, the Company has not seen a sustained downside impact on consumer demand in its core California market and has been able to fulfill orders without interruption. The Company believes it is well prepared to respond to this crisis. Please visit plusproductsinc.com/coronavirus to see the actions PLUS is taking to respond to this unique challenge.

(1) According to proprietary research conducted through HJR Associates, a third-party firm contracted by the Company
(2) PLUS had the largest gummies brand and two best-selling cannabis products in California for 2018 and 2019 according to BDS Analytics
(3) According to Arcview | BDS Analytics - State of the Legal Markets 7th Edition
(4) According to BDS Analytics for 2019

Conference Call Details

At 5:00 pm Eastern Time / 2:00 pm Pacific Time today (Thursday, May 28, 2020) the Company will host a conference call and webcast to discuss the financial results and its recent corporate highlights.

Participant Dial-In Numbers:

Toll-Free: (866) 220-4156

Toll / International: (864) 663-5231

*Participants should request the Plus Products Earnings Call or provide conference ID: 4754548

Please dial-in or log-on to the webcast at least 10 minutes before the start of the call

The call will also be webcast at https://edge.media-server.com/mmc/p/3sdhitpx. Please visit the website at least 15 minutes prior to the call to register, download, and install any necessary audio software. Following the conclusion of the call, there will be an archived audio webcast of the conference call available for replay on the Company’s website at PlusProductsInc.com.

Jake Heimark, Co-founder and Chief Executive Officer, and Jon Paul, Chief Financial Officer, will be conducting a question and answer session following the prepared remarks.

About PLUS

PLUS is a cannabis and hemp food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA.

For further information contact:

Jake Heimark
CEO & Co-founder
ir@plusproducts.com 

Investors:

Blake Brennan
Investor Relations
blake@plusproducts.com 
Tel +1 213.282.6987

Media:

Megan Sekkas
Public Relations
megan@sekkas.com 
Tel +310.279.6811

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (each, a “forward-looking statement”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not limited to, statements relating to: the Company’s expectations with respect to the reductions in cash and cash equivalents to continue to be substantially lower than those incurred throughout 2019; the impact of the material changes announced in March 2020 on the business of the Company and the extent to which such changes will provide an accelerated path towards becoming cash flow generative and the continued efforts by the Company to establish itself as a leader in the California edibles market; the extent to which the Company will focus on leveraging core capabilities to create capital-efficient growth through known distribution channels; the extent to which California will remain the most valuable market for building a branded products company in cannabis; the extent to which the Company believes it will grow its position in the market throughout the course of this year; and the extent to which the Company’s strategic objectives in 2020 are built around three critical items, and the extent to which the Company is already executing on these three objectives.

These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the success of the Company’s investments, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of the Company’s products, customer experience and retention, the continued development of adult-use sales channels, managements estimation of consumer demand in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete capital projects and facilities improvements, the ability to expand and maintain distribution capabilities, the impact of competition, the ability of the Company to implement initiatives and the possibility for changes in laws, rules, and regulations in the industry.

Further, the duration and severity of the current COVID-19 pandemic may significantly impact or exacerbate some of the above-listed risks and uncertainties.  Risks that may be further impacted by the COVID-19 pandemic relate to the Company’s operations and expansion, including the Company’s ability to grow its brand and sales and to maintain production levels in the event that the Company’s employees are restricted from accessing facilities for a significant period of time; to the Company’s ability to access capital and the level of borrowing costs; the Company’s ability service obligations under its debt securities and other debt or lease obligations; and the Company’s ability to comply with the covenants contained in the agreements that govern the Company’s existing indebtedness.

The transmission of COVID-19 and efforts to contain its spread have recently resulted in international, national and local border closings, travel restrictions, significant disruptions to business operations, supply chains and customer activity and demand (across all sectors), service cancellations, reductions and other changes, and quarantines, as well as considerable general concern and uncertainty.

The overall severity and duration of COVID-19-related adverse impacts on the Company’s business will depend on future developments that cannot currently be predicted. Even after the COVID-19 outbreak has subsided, the Company may continue to experience material adverse impacts to the businesses as a result of its global economic impact, including any related recession.

The Company is under no obligation and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Non-GAAP Measures:

Adjusted uncompressed weighted average shares outstanding and loss per share.

The Company has additionally determined the adjusted uncompressed weighted average shares outstanding and loss per share, basic and diluted. The Company believes these measures to be representative of loss and comprehensive loss on a per share basis; however, these performance measures have no standardized meaning. As such, there are likely to be differences in the method of computation when compared to similar measures presented by other issuers. Management believes that, in addition to conventional measures prepared in accordance with GAAP, some investors use this information to evaluate the Company’s performance. Accordingly, they are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP.

 
 
PLUS PRODUCTS INC.
Condensed Interim Consolidated Statements of Financial Position
(Expressed in U.S. Dollars - Unaudited)
  As at March 31, As at December 31, 
  2020 2019 
  $ $ 
Assets     
Current     
Cash and cash equivalents 14,168,389 15,176,184 
Trade receivables 3,318,914 4,040,183 
Prepaids and deposits 907,322 1,262,269 
Taxes recoverable 112,377 112,377 
Note receivable 200,000 200,000 
Inventory 3,172,068 3,872,175 
  21,879,070 24,663,188 
Non-current     
Prepaids and deposits 833,328 789,521 
Property and equipment 3,227,046 3,703,597 
Intangible assets 84,109 98,665 
      
Total assets 26,023,553 29,254,971 
      
Liabilities     
Current     
Accounts payable and accrued liabilities 1,783,128 2,289,393 
Income taxes payable   16,990 - 
Current portion of vehicle loans 27,999 27,753 
Current portion of lease liabilities 297,633 284,588 
    2,125,750 2,601,734 
Non-current     
Vehicle loans 130,345 137,588 
Lease liabilities 949,019 1,028,218 
Convertible debentures 16,139,005 17,188,223 
Total liabilities   19,344,119 20,955,763 
      
Shareholders' equity     
Share capital 41,720,119 41,782,711 
Reserves 7,778,271 7,884,184 
Deficit   (44,069,521)(41,138,127)
Accumulated other comprehensive loss   1,250,565  (229,560)
Total shareholders' equity   6,679,434  8,299,208 
      
Total liabilities and shareholders' equity   26,023,553  29,254,971 


PLUS PRODUCTS INC.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss
(Expressed in U.S. Dollars, except number of shares - Unaudited)
 Three Months Ended March 31, 
  2020 2019 
  $ $ 
Revenue 4,739,209 3,244,958 
Cost of sales 3,085,419 2,553,101 
Gross margin 1,653,790 691,857 
      
Operating expenses     
Advertising and promotion 386,675 227,300 
Depreciation and amortization 25,319 - 
Consulting fees 171,841 694,483 
General and administrative 460,719 460,301 
Meals and travel expenses 131,944 198,560 
Professional fees 381,987 874,301 
Regulatory fees 15,552 3,336 
Research and development 7,473 5,987 
Salaries and benefits 1,743,710 1,055,688 
Share-based compensation 394,547 179,629 
Loss from operations (2,065,977)(3,007,728)
      
Other (income) expense     
Interest and other income 1,490 (609)
Accretion finance income (43,807)- 
Accretion expense 430,907 349,028 
Interest expense 423,057 171,268 
Foreign exchange gain 36,780 (157,579)
Loss before income taxes (2,914,404)(3,369,836)
      
Income tax expense 16,990 75,024 
      
Loss for the period   (2,931,394)(3,444,860)
      
Currency translation adjustment   (1,480,125)- 
Loss and comprehensive loss for the period   (1,451,269)(3,444,860)
      
      
Basic and diluted 33,822,501 24,880,328 
      
      
Basic and diluted (0.09)(0.14)